

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

**For the month of June 2009**

**Commission File Number 000-28508**

**Flamel Technologies S.A.**

(Translation of registrant's name into English)

**Parc Club du Moulin à Vent  
33 avenue du Dr. Georges Levy  
69693 Vénissieux Cedex France**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark whether registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- \_\_\_\_\_

---

---

**INFORMATION FILED WITH THIS REPORT**

Document Index

99.1 Press release regarding new feasibility projects and technology access fee, dated June 22, 2009.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Flamel Technologies S.A.

Dated: June 22, 2009

By: /s/ Stephen H. Willard

Name: Stephen H. Willard

Title: Chief Executive Officer

---

## EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release regarding new feasibility projects and technology access fee, dated June 22, 2009.



FLAMEL TECHNOLOGIES

**Flamel Technologies Announces New Feasibility Projects;  
Technology Access Fee**

**LYON, France – June 22, 2009** – Flamel Technologies, SA (Nasdaq: FLML) today announced that it has entered into agreements with a leading global healthcare provider to assess the applicability of the Medusa® platform for controlled release formulations of therapeutic proteins. The Company will receive technology access fees totaling € 2.5 million pursuant to these agreements, plus full development costs for the program. A joint press release regarding the agreement is anticipated for release in mid July.

Stephen H. Willard, Chief Executive Officer of Flamel Technologies, said: “We are very pleased to add a new partner for multiple molecules using our Medusa technology. We are gratified that our technology has achieved the recognition which justifies upfront payments as well as the usual license fees, development fees, milestones, and royalties. We look forward to announcing additional details of our collaboration in the month to come.”

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel’s Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins and peptides, as well as small molecule drugs.

**Contact:**

Charles Marlio, Director of Strategic Planning and Investor Relations

FRANCE: + 33 (0) 4 7278-3434

Fax: + 33 (0) 4 7278-3435

[Marlio@flamel.com](mailto:Marlio@flamel.com)

*This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals and projections regarding financial results, product developments and technology platforms. All statements that are not clearly historical in nature are forward-looking, and the words “anticipate,” “assume,” “believe,” “expect,” “estimate,” “plan,” “will,” and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel’s reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel’s Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2008. All forward-looking statements included in this release are based on information available at the time of the release. We undertake no obligation to update or alter our forward-looking statements as a result of new information, future events or otherwise.*